What disease does Ravicti® Oral Solution 1.1 g/mL treat?

It is a treatment for Urea Cycle Disorder (UCD). UCD is a group of diseases where there is an abnormality in the metabolic pathway that converts toxic ammonia into non-toxic urea in the body.

What are the main features of Ravicti®?

Compared to existing sodium phenylbutyrate formulations, it requires a smaller dosage volume and is sodium-free, making it suitable for patients who need sodium restriction.

AI News NQ Analysis

Notice of New Release of Urea Cycle Disorder Treatment Drug 'Ravicti® Oral Solution 1.1 g/mL'

NQ Score 86/100

AI Summary (NQ-processed)

OrphanPacific Co., Ltd. announced the launch of 'Ravicti® Oral Solution 1.1 g/mL,' a new drug for urea cycle disorders (UCD), on April 15, 2026. This prodrug of phenylbutyrate received manufacturing and marketing approval in Japan on December 22, 2025. It offers advantages such as a smaller dosage volume and being sodium-free compared to existing treatments. The drug price is 41,455.40 yen, aiming to reduce the treatment burden for UCD patients and provide new therapeutic options.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What disease does Ravicti® Oral Solution 1.1 g/mL treat?: A: It is a treatment for Urea Cycle Disorder (UCD). UCD is a group of diseases where there is an abnormality in the metabolic pathway that converts toxic ammonia into non-toxic urea in the body.
Q: What are the main features of Ravicti®?: A: Compared to existing sodium phenylbutyrate formulations, it requires a smaller dosage volume and is sodium-free, making it suitable for patients who need sodium restriction.